Inflammatory condition of skin

This section encompasses a wide range of skin conditions, comprising a number of separate aetiologies. They fall into this category due to their common inflammatory pathology,

...


Read more on Inflammatory condition of skin

 

 

Latest news articles

Added 1 day ago Drug news

Tremfya filed with FDA for psoriatic arthritis.- Janssen Pharma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the...

Added 7 days ago Latest content updates

Long-term disease control in Psoriasis: announcing a new project

epgonline.org is pleased to announce a unique and interactive educational programme delivered through an educational grant with Almirall S.A

 

Added 22 days ago Drug news

Amgen to acquire Otezla from Celgene for $13.4 billion

Amgen has announced that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger...

Search all news articles for Inflammatory condition of skin
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Load more

Guidelines

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet (UV) light–based therapies, which include narrowband and broadband UVB, UVA in conjunction with photosensitizing agents...

Added 1 month ago

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations

The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process.

Added 1 year ago

British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018

The overall objective of the guidelines is to provide up-todate, evidence-based recommendations on the investigation and management of secondary pruritus without underlying skin disorder and generalized pruritus of unknown origin (GPUO) in adults...

Added 1 year ago

Search all guidelines for Inflammatory condition of skin
 

Journal articles

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.

Background: Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We aimed to compare the efficacy and safety of...

Added 13 days ago

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis.

Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease.

Added 13 days ago

Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.

Aim: Gordon et al. investigated the efficacy and safety of risankizumab [an anti‐interleukin (IL)‐23p19 biologic] compared with ustekinumab (anti‐IL‐12/23p40) and placebo in patients with moderate‐to‐severe chronic plaque psoriasis.

Added 13 days ago

Search all journal articles for Inflammatory condition of skin
 

Clinical trials

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.

Added 6 months ago

A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).

Added 6 months ago

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

Added 6 months ago

Search all clinical trials for Inflammatory condition of skin
 
Lisa Lishman

EULAR 2018 – Biosimilars: the future of rheumatology?

EULAR's Annual European Congress of Rheumatology aims to encourage innovation and collaboration across all aspects of rheumatology, something that is particularly well illustrated by biologics and their more affordable counterpart, biosimilars. Could they unlock the door to accessible, life-changing treatment for millions more?

CME

Psoriasis: diagnosis and individualised therapy

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
15

Ask an expert: Psoriasis

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Psoriasis: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Inflammatory condition of skin